Novavax Inc (NASDAQ:NVAX) shares have been halted since the pre-market session as the U.S. Food and Drug Administration holds a meeting to determine the fate of the company's COVID-19 vaccine.
A committee of independent FDA vaccination advisors have been assessing the safety of the company's vaccine on Tuesday at a FDA Advisory Committee meeting.
